Overview

Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC

Status:
Active, not recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

This study evaluates the efficacy of the new docetaxel-cisplatin-cetuximab regimen (TPEx) versus the standard platinum-5FU-cetuximab EXTREME regimen as a first-line treatment in recurrent and/or metastatic HNSCC. Half of patients will be treated by TPEx regimen, while the other half will be treated by EXTREME regimen.

Phase:

Phase 2

Details

Lead Sponsor:

Groupe Oncologie Radiotherapie Tete et Cou

Collaborators:

AIO-Studien-gGmbH
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Treatments:

Cetuximab
Cisplatin
Docetaxel
Lenograstim
Sargramostim